Scholarlink

<p>Cytokine treatment provides clinical benefits by stimulating the patient’s immune system to attack cancer cells. However, its effectiveness as a monotherapy is limited because of its systemic toxicity and short in vivo half-life. To address these limitations, we assessed the therapeutic impact of delivering cytokines specifically to tumors using tumor-targeting bacteria. A <i>Salmonella</i> strain was engineered to minimize its pathogenic traits by deleting key elements (<i>Salmonella</i> pathogenicity islands-1 and -2) responsible for invasion and replication within the mammalian host, generating the ΔSPI-1ΔSPI-2 strain. A plasmid encoding a synthetic type 3 secretion system (SynT3SS V3.0) was introduced into this strain using a previously reported genetic system after reorganizing the gene clusters and placed under control of the P<sub>tet</sub> promoter. Finally, the anticancer cytokine Neoleukin-2/15 (Neo-2/15) was introduced into the strain via a separate plasmid. This plasmid encoded an N-terminal secretion signal from SptP (SptP<sub>167</sub>) and was driven by the constitutive promoter P<sub>J23110</sub>. Upon inducing SynT3SS V3.0 using doxycycline, the recombinant protein SptP<sub>167</sub>::Neo-2/15 was secreted into the bacterial culture supernatant with a yield of 0.37 ± 0.07&#xa0;mg/L. Starved cytotoxic T lymphocytes treated with the culture supernatant containing SptP<sub>167</sub>::Neo-2/15 proliferated, as observed with hIL-2, purified Neo-2/15, or purified SptP<sub>167</sub>::Neo-2/15 treatment. Administering <i>Salmonella</i> ΔSPI-1ΔSPI-2 strains carrying plasmids encoding SynT3SS V3.0 and SptP<sub>167</sub>::Neo-2/15 caused tumor regression and lifespan extension in CT26 tumor-bearing mice. Engineered bacteria represent a promising new modality for cancer therapy by combining the targeted delivery of therapeutic cytokines with the synergistic immunostimulatory effects of bacterial intrinsic factors. Furthermore, this strategy could be adapted for other protein-based payloads, potentially enabling the tumor-specific delivery of a diverse range of therapeutic agents.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Tumor-specific cytokine therapy mediated by engineered Salmonella with a synthetic protein delivery system

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月19日

查看全文
  • Jaewon Ha,
  • Miryoung Song

摘要

Cytokine treatment provides clinical benefits by stimulating the patient’s immune system to attack cancer cells. However, its effectiveness as a monotherapy is limited because of its systemic toxicity and short in vivo half-life. To address these limitations, we assessed the therapeutic impact of delivering cytokines specifically to tumors using tumor-targeting bacteria. A Salmonella strain was engineered to minimize its pathogenic traits by deleting key elements (Salmonella pathogenicity islands-1 and -2) responsible for invasion and replication within the mammalian host, generating the ΔSPI-1ΔSPI-2 strain. A plasmid encoding a synthetic type 3 secretion system (SynT3SS V3.0) was introduced into this strain using a previously reported genetic system after reorganizing the gene clusters and placed under control of the Ptet promoter. Finally, the anticancer cytokine Neoleukin-2/15 (Neo-2/15) was introduced into the strain via a separate plasmid. This plasmid encoded an N-terminal secretion signal from SptP (SptP167) and was driven by the constitutive promoter PJ23110. Upon inducing SynT3SS V3.0 using doxycycline, the recombinant protein SptP167::Neo-2/15 was secreted into the bacterial culture supernatant with a yield of 0.37 ± 0.07 mg/L. Starved cytotoxic T lymphocytes treated with the culture supernatant containing SptP167::Neo-2/15 proliferated, as observed with hIL-2, purified Neo-2/15, or purified SptP167::Neo-2/15 treatment. Administering Salmonella ΔSPI-1ΔSPI-2 strains carrying plasmids encoding SynT3SS V3.0 and SptP167::Neo-2/15 caused tumor regression and lifespan extension in CT26 tumor-bearing mice. Engineered bacteria represent a promising new modality for cancer therapy by combining the targeted delivery of therapeutic cytokines with the synergistic immunostimulatory effects of bacterial intrinsic factors. Furthermore, this strategy could be adapted for other protein-based payloads, potentially enabling the tumor-specific delivery of a diverse range of therapeutic agents.